Everything
you want in a
CDMO in one campus
End-to-End Development &
Manufacturing Services
Please share your details to book a meeting with Syngene during DCAT week
Why Syngene
Full-scale, integrated CDMO
28+ years of experience and 420+ active global clients
Wide industry experience
Across pharma, biotech, nutrition, animal health, consumer goods and speciality chemical companies
Expert, multi-disciplinary team
5200+ scientists and 400+ patent credits
Full, value-chain capabilities in one campus
Supply chain, procurement, logistics, delivery, technology transfer and regulatory
International accreditations
US FDA, EMA and PMDA approved; GLP, GMP, ISO certified; AAALAC, ANVISA accredited facilities
Regulatory experience
Across IND and IMPD dossier preparation for regulatory approvals
Flexible and varied business models
Stand-alone services and defined, integrated activity bundles
Continuous process improvement
For increased productivity and faster turn-around time
DCAT week is a much-anticipated event every year offering opportunities to both biopharma companies and CRO/CDMOs to network, learn and grow together.
As a leading CRO/CDMO, Syngene offers integrated, end-to-end development and manufacturing services from one campus to easily advance clinical candidates from Preclinical to NDA filing. Our high-end capabilities extend across the Development lifecycle spanning Process R&D, Formulation Development (including Clinical Supplies), Analytical R&D, ICH Stability Studies, Clinical Development, and Commercial Manufacturing.
In biologics, we have expertise in recombinant proteins, glycoproteins, mAbs, antibody fragments, bispecifiÂcs, and microbiome (live biotherapeutics). We offer GMP manufacturing capacity of 2000L for mammalian using single-use bioreactors and up to 500L for microbial using stainless steel fermenters.
In Discovery services, we have the full range of capabilities to support both small molecules and biologics discovery projects — Target ID and validation to candidate selection, and on to phase 1 studies
As a leading CRO/CDMO, Syngene offers integrated, end-to-end development and manufacturing services from one campus to easily advance clinical candidates from Preclinical to NDA filing. Our high-end capabilities extend across the Development lifecycle spanning Process R&D, Formulation Development (including Clinical Supplies), Analytical R&D, ICH Stability Studies, Clinical Development, and Commercial Manufacturing.
In biologics, we have expertise in recombinant proteins, glycoproteins, mAbs, antibody fragments, bispecifiÂcs, and microbiome (live biotherapeutics). We offer GMP manufacturing capacity of 2000L for mammalian using single-use bioreactors and up to 500L for microbial using stainless steel fermenters.
In Discovery services, we have the full range of capabilities to support both small molecules and biologics discovery projects — Target ID and validation to candidate selection, and on to phase 1 studies
Meet our experts
Jonathan Hunt
Chief Executive Officer & Managing Director
Mahesh Bhalgat
Chief Operating Officer
Alex Del Priore
Sr. Vice President – Manufacturing Services
Purushottam Singnurkar
Vice President, Formulations Development
Ian Grundy
VP Sales Europe/ROW - Development & Manufacturing Services
Nageswara Rao
VP Business Development - Clinical Development services
Pravinkumar Prajapati
Director, Business Development, Biologics
Disha Gupta
Director of Sales North America - Development & Manufacturing services
Insights and Resources
Small Molecule Development and Manufacturing
Syngene offers chemical development, formulation, analytical, clinical development, and manufacturing services across small molecules, oligonucleotides, HPAPIs, and performance and specialty materials.
Biologics Development and Manufacturing
Syngene offers chemical development, formulation, analytical, clinical development, and manufacturing services across small molecules, oligonucleotides, HPAPIs, and performance and specialty materials.
Clinical Development
Syngene offers BA/BE studies for generic drugs, clinical trial management (Phase1-3), central laboratory services, regulated bioanalytical lab services, clinical data management, and biometric services.
Discovery Services
Syngene offers integrated and standalone services across the drug discovery continuum, from Target Identification to IND enabling services.
Syngene International Limited. All rights reserved © 2023